Advances in HSCT: Highlights From the 2013 BMT Tandem Meetings

Slides:



Advertisements
Similar presentations
台北榮總血液腫瘤科 楊元豪 / 高志平大夫. 2 Background Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is the only potentially curative treatment in patients.
Advertisements

Congenital Neutropenia: Making the Decision to Transplant John E. Levine, MD, MS University of Michigan Blood and Marrow Transplantation Program.
A single centre study of the efficacy of extracorporeal photopheresis in Acute Graft Versus Host Disease Lynne Watson Nottingham University Hospital NHS.
Hematopoietic stem cell transplantation
Jeffrey Schriber, M.D. FRCP (c) Medical Director Cancer Transplant Institute Virginia G. Piper Cancer Center Everything You Ever Wanted to Know About Transplant.
Safe and Effective Re-Induction of Complete Remissions in Adults with Relapsed B-ALL Using 19-28z CAR CD19-Targeted T Cell Therapy Davila ML et al. Proc.
Current Uses and Outcomes of Hematopoietic Stem Cell Transplantation 2010 CIBMTR Summary Slides SUM10_1.ppt.
Lee DW III et al. Proc ASH 2013;Abstract 68.
AUTOLOGOUS AND ALLOGENEIC TRANSPLANTATION IN MULTIPLE MYELOMA Vienna, May, 2014 Montserrat Rovira, Laura Rosiñol, Enric Carreras Hospital Clinic, Barcelona.
1 Transplant and Cellular Therapy Unit Institut Paoli Calmettes Inserm U599 Université de la Méditerranée Marseille, France ALLOGENEIC STEM CELL TRANSPLANTATION.
Hematopoietic stem cell transplantation- HSCT. Principle of HSCT Myeloablation and eradication of residual disease with hogh dose conditioning regimen.
2 nd International Conference on Hematology & Blood Disorders ( Sep. 29-Oct. 01, 2014 Baltimore, USA ) Hyogo College of Medicine Graft-versus-GVHD, a second.
Optimal Use of Transplant for Myeloma Early-Late-nonablative Koen van Besien, MD, PhD Weill Cornell Medical College.
CTC report Bronwen Shaw – chair Andy Peniket – secretary
Allogeneic “Mini” Transplantation Mark B. Juckett M.D. June 4, 2004.
Treatment Multiple Myeloma. Symptomatic/progressive myeloma: Systemic therapy - to control progression of myeloma Supportive care - to prevent serious.
Bone marrow Transplant in Paediatric Haematology
TREATMENT. Phases of treatment Induction chemotherapy Postremission therapy *Initial goal: quickly induce CR *Therapy depends on patient age.
Treatment. Phases of treatment Induction chemotherapy Postremission therapy *Initial goal: quickly induce CR *Therapy depends on patient age.
Due to the non-myeloablative nature of the reduced intensity conditioning, following infusion there is a period of mixed-chimerism with both patient and.
Abstract Immune Reconstitution and Clinical Outcome After Donor Lymphocyte Infusion for Relapsed Disease After Reduced-Intensity Allogeneic Hematopoietic.
P Ferguson, R Hills, A Grech, L Kjeldsen, M Dennis, P Vyas, R Clark, N Russell, C Craddock, On behalf of the NCRI AML Working Group. An operational definition.
G. Lucchini on behalf of the EBMT PDWP SCT in pediatric AML in 1CR: does the conditioning regimen matter? Scientific Day 12 th May, 2016 London.
Survey summary PTCL clinical practice recommendations
Stem Cell Transplantation
AUTOLOGOUS AND ALLOGENEIC TRANSPLANTATION IN MULTIPLE MYELOMA
RIC UCBT Transplantation of Umbilical Cord Blood from Unrelated Donors in Patients with Haematological Diseases using a Reduced Intensity Conditioning.
19-28z CAR T-Cell Efficacy and Toxicity in Adults With R/R B-Cell ALL
Retrospective analysis of conditioning regimen containing decitabine of allogeneic stem cell transplantation for myelodysplastic syndrome and myeloproliterative.
Supplemental table 1 Patients' characteristics Variables Number
Shahad Abbas1,2 Alison H Thomson1,2 B) non-malignant patients.
Program Goals. Program Goals Immunotherapy of B-cell Malignancies.
Pharmacy Perspectives in Multiple Myeloma: Relapsed and/or Refractory Disease.
Learning Goals. Harnessing the Immune System: Mechanism of Action of Immunotherapies in B-Cell Malignancies.
Updates in Hodgkin Lymphoma
Allogeneic stem cell transplantation (allo-SCT) is a potentially curative procedure for a variety of malignant and nonmalignant conditions. Historically,
Optimizing the Treatment of Recurrent/Metastatic SCCHN
Treating Transplant-Ineligible Patients With Multiple Myeloma
Clinical Challenges in the Transplant-Eligible Patient With Newly Diagnosed Multiple Myeloma.
Functional Myeloid-Derived Suppressor Cell Subsets Recover Rapidly after Allogeneic Hematopoietic Stem/Progenitor Cell Transplantation  Qingdong Guan,
PREDICTIVE FACTORS AFFECTING THE OUTCOME OF ALLOGENEIC STEM CELL TRANSPLANTATION USING RIC REGIMENS: EXPERIENCE FROM A SINGLE CENTRE Dott.ssa M. Medeot.
Expert Perspectives on HSCT: Planning for Success
Intravenous Busulfan-Cyclophosphamide as a Preparative Regimen Before Allogeneic Hematopoietic Stem Cell Transplantation for Adult Patients with Acute.
The Emerging Role of Immunotherapy in Hodgkin Lymphoma
Assessment of Allogeneic HCT in Older Patients with AML and MDS: A CIBMTR Analysis McClune B et al. ASCO/ASH Symposium 2009;The Best of ASH Special & Plenary.
ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION for MULTIPLE MYELOMA
Multiple Myeloma Overview all transplants, autologous and allogeneic (period ) N=28.887
Advances in Multiple Myeloma: Data Highlights and Analysis from the 2015 Hematology/Oncology Conferences.
Introduction Case Report Conclusion
Letermovir(Prevymis™) Guidelines for Inpatient Use
Qualitative and quantitative PCR monitoring of minimal residual disease (MRD) in relapsed poor-risk chronic lymphocytic leukemia (CLL): early assessment.
What Does It Take to Be a Long-Acting Replacement Therapy in Hemophilia A?
Hematopoietic Stem Cell Transplantation for Patients with AML
CMV in the HSCT Recipient
A Single-Center Experience Comparing Alemtuzumab, Fludarabine, and Melphalan Reduced-Intensity Conditioning with Myeloablative Busulfan, Cyclophosphamide,
Patient-Centered Management in Advanced Non-Small Cell Lung Cancer
Practical Guidance on the Management of Pan-Negative NSCLC
Blinatumomab Versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia
Short title / Key scientific finding
Lower Dose of Antithymocyte Globulin (ATG) Decreases Infection Rate without Increasing Graft-Vs-Host Disease (GVHD) and Relapse in Patients Undergoing.
JAK2 INHIBITORS AND ALLOGRAFTING
A Well-Tolerated Regimen of 800 cGy TBI-Fludarabine-Busulfan-ATG for Reliable Engraftment after Unmanipulated Haploidentical Peripheral Blood Stem Cell.
Effect of Conditioning Regimen Intensity on Acute Myeloid Leukemia Outcomes after Umbilical Cord Blood Transplantation  Betul Oran, John E. Wagner, Todd.
CD34-Selected Allogeneic Hematopoietic Stem Cell Transplantation for Patients with Relapsed, High-Risk Multiple Myeloma  Eric Smith, Sean M. Devlin, Satyajit.
Improved Outcome for Peripheral Blood Stem Cell Transplantation for Advanced Primary Myelodysplastic Syndrome  Scott R. Solomon, Bipin N. Savani, Richard.
Clinical Lymphoma, Myeloma and Leukemia
Clinical Pearls in the Management of Patients With Advanced Non-Small Cell Lung Cancer.
Diagnostic Criteria Migraine Without Aura
Clinical Challenges in the Transplant-Eligible Patient With Newly Diagnosed Multiple Myeloma.
Graft-versus-Host Disease: State of the Science
Presentation transcript:

Advances in HSCT: Highlights From the 2013 BMT Tandem Meetings

CARS

Responses From CART19 Treatment

Immunotherapy for Eradicating Residual Disease in Myeloma

Phase 1/2: HDACi as a Novel Strategy for Prevention of Acute GVHD

Allo-SCT in Patients Age > 70 y

Cord Colitis Syndrome

Impact of Mixed Chimerism

CD19-Targeted T Cells for Chemotherapy-Refractory ALL

MAC or RIC for Cord Blood Transplants

MAC or RIC for Cord Blood Transplants (cont)

Double- vs Single-Cord Transplants

CIBMTR Study: IV BU vs TBI-based MAC

Higher Dose BU RIC Regimen May Benefit a Subset of Patients

Administering IV BU to Achieve Optimum AUC

CLO/MEL as Conditioning Regimen

TLI-ATG Conditioning

Abbreviations

Abbreviations (cont)

Abbreviations (cont)

Abbreviations (cont)

Abbreviations (cont)

References

References (cont)

References (cont)

References (cont)

References (cont)

References (cont)

References (cont)

References (cont)

References (cont)

References (cont)

References (cont)

References (cont)

References (cont)

References (cont)

References (cont)

References (cont)

References (cont)

References (cont)

References (cont)